Aminotadalafil (CAS 385769-84-6) is an organic compound used in pharmaceutical research and development, primarily as an analogue of tadalafil and a phosphodiesterase 5 (PDE5) inhibitor, for laboratory research and drug development in the treatment of erectile dysfunction, pulmonary hypertension, and lower urinary tract dysfunction.
Aminotadalafil is a derivative or metabolite analog of tadalafil, with an amino group modified in its molecular structure, which helps researchers explore the structure-activity relationship of PDE5 inhibitors.
Activity testing can assess the impact of amino acid modification on drug solubility, metabolic stability, and target selectivity; it also provides structural optimization strategies for developing next-generation drugs for treating erectile dysfunction (ED), such as improving onset of action or reducing side effects.
As an effective PDE5 inhibitor, it promotes smooth muscle relaxation and increased blood flow by inhibiting the breakdown of cyclic guanosine monophosphate (cGMP) and enhancing the nitric oxide (NO) signaling pathway.